Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate reported to date with sustained clinical ben

  • Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of responders remaining cancer-free at one year after CR1